Multiplex DNA Stool Technology for the Integrative and Functional Medicine Practitioner

 

The GI-MAP™ (GI-Microbial Assay Plus) test is the first comprehensive stool analysis to include an FDA-approved DNA/PCR assay for GI pathogens performed on stool*. The pathogen targets include bacteria, parasites and another first for the market, viruses!

Using the same molecular technology, we have developed assays for microbes that are useful for integrative and function medicine practitioners. And unlike previous PCR (polymerase chain reaction) assays, we have fully validated each target organism in our panel, so that you can have confidence in the results.

GI-MAP™ tests for GI pathogens, opportunistic organisms, normal flora, and markers of GI health including:

  • Bacteria
  • Viruses
  • Parasites
  • Fungi
  • Inflammation
  • Immune function
  • Pancreatic function
  • Occult blood
unnamed-18.jpg
DNA/PCR techniques also allow for the measurement of antibiotic resistance genes and virulence factors that contribute to pathogenicity. Both are used to help determine clinical significance and the most effective treatments.
 
GI-MAP™The Superior Solution

Other available stool tests may appear to be DNA-based, but they are in fact only using matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) to identify stool microbes. Their methodology relies on cultures from stool and is not molecular/PCR based assays. With a culture-based test it is not possible to measure strict anaerobes, viruses or virulence factors. They also lack the ability to deliver true quantitation of any of the reported organisms.

In addition, other recent test offerings using an FDA-cleared molecular technology only for pathogens do not extend any molecular methodology over an entire comprehensive stool analysis to include opportunistic and beneficial organisms, including bacteria, protozoa, and fungi, all of which are provided through the GI-MAP™.

There have been many advances in DNA technology over the last 10 years, including an FDA approved, PCR based technology and assay that is used by major hospital labs. Considering these advances, why would you still rely on culture and microscopy for stool analysis and assessment of the GI environment?

 

Diagnostic Solutions Laboratory

GI-MAP™ was developed by Diagnostic Solutions Laboratory (DSL). DSL was founded to bridge the gap between healthcare providers and the clinical laboratory. Their commitment is to serve the clinical needs of the health care provider with cutting-edge laboratory medicine by utilizing proven methodologies that are accurate and reliable. By working with experienced clinicians and opinion leaders throughout multiple medical disciplines, they are able to build assays that are clinically relevant and provide actionable results.

The highly experienced scientists at DSL have developed over 500 assays in their careers. They are empowered to validate every analyte and use the best methodology available to be sure the results you receive are accurate and precise. Their production team adheres to the strictest standards with an emphasis on quality and a realization that every sample belongs to a patient. Customer service and technical support teams are dedicated to helping patients, clinicians and their staff understand our testing and the process of working with Diagnostic Solutions Laboratory in a seamless manner.

 

* GI pathogens are performed using the Luminex GGP assay developed and patented by Luminex Corporation.

Shadow-Bar_2.png

Watch the DFH Webinar:

Designs for Health and Diagnostic Solutions Laboratory Present Advances in Testing of the GI Microbiota

White Paper download:

 GI-MAP™ DNA Stool Analysis

GI_Map_Thumbnails-02.jpg
GI_Map_Thumbnails-01.jpg
Shadow-Bar_2.png